Kensuke Naruto, Tomokazu Kawaoka, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Yusuke Johira, Shigeki Yano, Kei Amioka, Yutaro Ogawa, Yuki Yoshikawa, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Yasutomo Fujii, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Shiro Oka
BACKGROUND: Zoledronic acid reduces the risk of bone metastasis, but denosumab is a better option for treating bone metastases. However, few studies have evaluated the use of denosumab to treat bone metastasis originating from hepatocellular carcinoma. This study aimed to assess the clinical outcomes of switching from zoledronic acid to denosumab for treating bone metastasis in patients with hepatocellular carcinoma. METHODS: This prospective study enrolled 10 patients with HCC and bone metastases...
November 2023: Yonago Acta Medica